How Not to Do An Acquisition: AstraZeneca-MedImmune
Jul
10
When AstraZeneca ponied up more than $15 billion for the biotech MedImmune just over a year ago, the deal suggested that desperate Big Pharmas were willing to open their wallets wide for biotechs without looking too closely into the …
Filed under: To-do, advertising, auto, dictionary, energy, food, health-care, investment, johnson-johnson, management, media, mobile, pharma, pharma-industry, retail, stocks, stumbleupon, technology, to-do, travel, video